Print Page     Close Window     

SEC Filings

DEF 14A
SEELOS THERAPEUTICS, INC. filed this Form DEF 14A on 04/12/2019
Entire Document
 

TABLE OF CONTENTS

Non-Employee Director Compensation for 2018

Below is a summary of the non-employee director compensation paid in fiscal 2018:

Name
Cash
Compensation(1)
Option Grants(2)
Stock Awards(3)
Total
Kleanthis G. Xanthopoulos, Ph.D.
$
92,000
 
$
96,710
 
$
 
$
188,710
 
Russell Ray
$
55,000
 
$
67,697
 
$
 
$
122,697
 
Paul V. Maier
$
58,000
 
$
67,697
 
$
 
$
125,697
 
Wendell Wierenga, Ph.D.
$
48,000
 
$
67,697
 
$
 
$
115,697
 
Sandford D. Smith
$
52,000
 
$
67,697
 
$
 
$
119,697
 
(1)Includes the value of the annual retainers payable to our non-employee directors.
(2)Represents the grant date fair value of the stock options granted in 2018, computed in accordance with FASB ASC Topic 718. As of December 31, 2018, each of our non-employee directors held stock options to purchase the following number of shares of our Common Stock: Dr. Xanthopoulos, options to purchase 64,034 shares; Mr. Ray, options to purchase 42,784 shares; Mr. Maier, options to purchase 43,684 shares; Dr. Wierenga, options to purchase 47,084 shares; and Mr. Smith, options to purchase 45,584 shares.
(3)No stock awards were granted to the directors in 2018.

Equity Compensation Plan Information

The following table gives information as of December 31, 2018 about shares of our Common Stock that may be issued upon the exercise of options and restricted stock units under both of our existing equity compensation plans:

Plan category
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
(a)(1)
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)(2)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a)(3)
Equity compensation plans approved by security holders
 
38,416
 
$
185.98
 
 
10,872
 
(1)Consists of options and restricted stock units outstanding as of December 31, 2018 under the 2012 Plan, and the 2006 Plan.
(2)Consists of the weighted average exercise price of outstanding options as of December 31, 2018.
(3)Consists entirely of shares of common stock that remain available for future issuance under the 2012 Plan as of December 31, 2018.

25


© Apricus Biosciences, Inc.